AR061663A1 - Procesos para la preparacion de inhibidores de iv dpp. composiciones farmaceuticas y compuestos relacionados. - Google Patents

Procesos para la preparacion de inhibidores de iv dpp. composiciones farmaceuticas y compuestos relacionados.

Info

Publication number
AR061663A1
AR061663A1 ARP070102855A ARP070102855A AR061663A1 AR 061663 A1 AR061663 A1 AR 061663A1 AR P070102855 A ARP070102855 A AR P070102855A AR P070102855 A ARP070102855 A AR P070102855A AR 061663 A1 AR061663 A1 AR 061663A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
preparation
pharmaceutical compositions
processes
Prior art date
Application number
ARP070102855A
Other languages
English (en)
Inventor
Abraham Thomas
Ashok Bhausaheb Kadam
Suresh M Kadam
Shantaram Kashinath Phatangare
Deepak Vital V
V S Prasada Rao Lingam
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of AR061663A1 publication Critical patent/AR061663A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sal farmacéuticamente aceptable del mismo, para el tratamiento de la diabetes Tipo 2.Composiciones farmacéuticas que lo contienen Reivindicacion 1: Un proceso para la preparacion de un compuesto de la formula 1, y esteroisomeros de los mismos, en donde X es un cicloalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, arilo sustituido o no sustituido, aralquilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, anillo heterocíclico sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, o heteroarilalquilo sustituido o no sustituido, y R es alquilo C1-4, que comprende el paso de condensar el compuesto de la formula 2 con un éster de ácido glioxálico.
ARP070102855A 2006-06-27 2007-06-27 Procesos para la preparacion de inhibidores de iv dpp. composiciones farmaceuticas y compuestos relacionados. AR061663A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1008MU2006 2006-06-27
IN1009MU2006 2006-06-27
US80732706P 2006-07-13 2006-07-13
US83169706P 2006-07-17 2006-07-17

Publications (1)

Publication Number Publication Date
AR061663A1 true AR061663A1 (es) 2008-09-10

Family

ID=38626165

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102855A AR061663A1 (es) 2006-06-27 2007-06-27 Procesos para la preparacion de inhibidores de iv dpp. composiciones farmaceuticas y compuestos relacionados.

Country Status (5)

Country Link
US (1) US7893103B2 (es)
EP (1) EP2035395A2 (es)
AR (1) AR061663A1 (es)
TW (1) TW200808770A (es)
WO (1) WO2008001195A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
NZ604091A (en) 2008-08-15 2014-08-29 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
WO2010079433A2 (en) * 2009-01-07 2010-07-15 Glenmark Pharmaceuticals, S.A. Pharmaceutical composition that includes a dipeptidyl peptidase-iv inhibitor
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ593361A (en) * 2009-01-09 2012-12-21 Orchid Res Lab Ltd Dipeptidyl peptidase iv inhibitors
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
AU2010212823B2 (en) 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7639M (es) 1967-09-14 1970-02-02
JP4357293B2 (ja) * 2001-06-27 2009-11-04 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
AU2002360732A1 (en) * 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
JPWO2004050654A1 (ja) * 2002-11-29 2006-03-30 塩野義製薬株式会社 ピロリジン化合物の合成とその塩
AU2003902260A0 (en) * 2003-05-09 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
JPWO2005016880A1 (ja) * 2003-08-18 2007-11-01 大正製薬株式会社 ｃｉｓ−４−フルオロ−Ｌ−プロリン誘導体の製造法
WO2005075426A1 (en) * 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
WO2006011035A1 (en) * 2004-07-23 2006-02-02 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; process for their preparation and compositions containing them
EP1799639B1 (en) 2004-10-12 2013-09-04 Glenmark Pharmaceuticals S.A. Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation

Also Published As

Publication number Publication date
EP2035395A2 (en) 2009-03-18
US20080076818A1 (en) 2008-03-27
WO2008001195A2 (en) 2008-01-03
US7893103B2 (en) 2011-02-22
TW200808770A (en) 2008-02-16
WO2008001195A3 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
AR061663A1 (es) Procesos para la preparacion de inhibidores de iv dpp. composiciones farmaceuticas y compuestos relacionados.
EA201500266A1 (ru) Ингибиторы репликации вирусов гриппа
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR053415A1 (es) Inhibidores dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procesos para la preparacion de los compuestos y de la composicion
AR091857A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
EA014959B3 (ru) Ингибиторы глицинового переносчика-1
EA200970170A1 (ru) Производные 4-триметиламмоний-3-аминобутирата и 4-триметилфосфоний-3-аминобутирата как ингибиторы срт
TNSN07395A1 (en) Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
AR123784A1 (es) Derivados de tetrazol como inhibidores de trpa1
EA200900481A1 (ru) Новые соединения индола, способ их получения и фармацевтические композиции, которые их содержат
WO2009021957A3 (en) Tricyclic heterocyclic compounds as gaba a modulators
EA200900480A1 (ru) Новые соединения индола, способ их получения и фармацевтические композиции, которые их содержат
EA201000832A1 (ru) Замещённые 3-гидроксипиридины и содержащие их фармацевтические композиции
EA201000867A1 (ru) Новые соединения 2-меркаптоциклопентанкарбоновой кислоты, способ их получения и содержащие их фармацевтические композиции
SE0400440D0 (sv) Novel Cinnamic Amides
TH83713B (th) อนุพันธ์ 2-(ไซคลิกอะมิโนคาร์บอนิล)อินโดลีน และ ส่วนผสมทางเภสัชกรรมที่มีสารนี้อยู่
AR132973A1 (es) Compuestos para el tratamiento de trastornos neurológicos
JOP20250073A1 (ar) مركبات سلفوكسيمين كمثبط دياسيتيلاز هيستون 6، وتركيبة صيدلانية تشتمل عليها
TH83713A (th) อนุพันธ์ 2-(ไซคลิกอะมิโนคาร์บอนิล)อินโดลีนและส่วนผสมทางเภสัชกรรมที่มีสารนี้อยู่
TH96085A (th) พิริดีน แอนาลอก iii 334 ชนิดใหม่
TH96576A (th) อนุพันธ์ของกรดฟีนิลอะซิติก ในฐานะเป็นสารยับยั้ง cox-2
BRPI0607087A2 (pt) derivados de oximas heterocìclicos, o respectivo processo de preparo e as composições farmacêuticas que os contêm
TH94332A (th) ตัวยับยั้งแกมมาซีครีเตสกลุ่มไตรไซคลิกซัลโฟนาไมด์ชนิดวงแหวนเชื่อมติด

Legal Events

Date Code Title Description
FB Suspension of granting procedure